Broadway’s 2024-25 season has gotten off to a rather extraordinarily fine start, from the wildly popular and hysterically funny Oh, Mary! to the fabulous splash of Death Becomes Her and the wonderful ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

That view was echoed by Intellia's chief executive, John Leonard, who said the data "underscore[s] the tremendous potential of [the] in vivo CRISPR gene editing therapy" and "sets NTLA-2002 apart ...